What is Causaly?
Causaly is at the forefront of redefining human discovery within the Life Science sector by harnessing advanced AI technologies. Established in 2018, the company's proprietary AI platform serves as a powerful catalyst for modern research organizations, fundamentally reshaping how critical data is identified, analyzed, and applied in the complex processes of drug discovery and development. Causaly's innovative approach aims to accelerate scientific breakthroughs and enhance decision-making for its clients.
How much funding has Causaly raised?
Causaly has raised a total of $81.8M across 3 funding rounds:
Series A
$4.8M
Unspecified
$17M
Series B
$60M
Series A (2019): $4.8M with participation from Marathon Venture Capital, Pentech Ventures, and EBRD Venture Capital
Unspecified (2021): $17M led by EBRD, Pentech, Marathon, and Index Ventures
Series B (2023): $60M supported by Index Ventures, ICONIQ Growth, Marathon Venture Capital, and Pentech
Key Investors in Causaly
Index Ventures
Index Ventures is a venture firm investing in the next generation of entrepreneurs from seed to IPO. They partner with founders with bold dreams that challenge the status quo to build enduring companies.
ICONIQ Growth
ICONIQ Growth partners with exceptional entrepreneurs and leaders who drive global impact and change, focusing on building enduring company cultures and amplifying portfolio company success.
Marathon Venture Capital
Marathon Venture Capital is a seed-stage fund dedicated to assisting ambitious Greek and European founders in building world-class technology companies, providing comprehensive support and expertise.
What's next for Causaly?
With the recent major strategic investment, Causaly is poised for accelerated growth and enhanced market penetration. The substantial capital infusion, bringing the total funding to $81.8M, will likely be directed towards further developing its AI platform, expanding its research and development capabilities, and scaling its operations to meet the growing demand in the Life Science industry. This strategic financing round, including backing from prominent investors, suggests a strong market validation and positions Causaly to further solidify its role as a leader in AI-driven drug discovery and development.
See full Causaly company page
